Olema announced the completion of enrollment in its Phase 3 OPERA-01 trial, with top-line data now expected in Q1 2027. The milestone shifts near-term focus away from enrollment progress and toward data quality and readout timing, potentially weighing on sentiment until results arrive. The key question is whether the readout will demonstrate meaningful efficacy and safety signals that could influence future indication and commercialization plans.
Olema Pharmaceuticals is experiencing a decline in stock price after Roche announced unsuccessful results from its phase 3 breast cancer trial. This news could impact investor sentiment towards OLMA, particularly given the competitive pressures in breast cancer therapies, potentially creating a buying opportunity if fundamentals remain strong.
Roche's phase 3 giredestrant results showed significant patient survival improvement. Olema (OLMA) stock surged about 137% intraday after the Roche news. Multiple analysts raised OLMA price targets, including Oppenheimer and JPMorgan. Martin Shkreli publicly announced a short position against OLMA, increasing volatility.
OLMA shares surged over 200% after Roche's positive SERD phase 3 lidERA results. Session volume spiked to 45.12M versus a 1.171M average, indicating heavy buying. Roche's giredestrant met the primary endpoint, improving invasive disease‑free survival. Oppenheimer raised palazestrant probability of success and OLMA price target to $45.
Olema's palazestrant shows promising clinical data for breast cancer treatment. Shares up over 70% in the last three months, boosting investor confidence. Analysts target price suggests potential 164% upside for Olema's stock. Key clinical trial results expected in 2026 may drive further growth. Palazestrant targets ER+ population, improving upon existing therapies.
